The thesis
SilentDip rests on a tidy behavioural premise: a sharp price drop without a negative headline is more likely noise than news. Such drops tend to revert to the mean, while the same move carrying genuine bad news keeps drifting lower. The strategy therefore requires two conditions to coincide — oversold technicals and the absence of salient negative sentiment — before it buys. Exits come as names mean-revert to their SMA20 or as RSI normalizes.
The idea is grounded in recent literature: Clinch, He, Landsman & Li's November 2025 SSRN working paper on temporal changes in delayed price reactions, itself extending Chan's well-known 2003 work on price reactions to news versus no-news. That is a reassuring pedigree — the strategy is implementing a documented effect, not reverse-engineering one from a price series.
Recent activity
SilentDip went live on 2026-10-11 with a $10,000 paper allocation and a clean reviewer approval (risk score 0.32), flagged as a "safe mean-reversion strategy." Activity since has been sparse, which is in character for a strategy that waits for a specific setup: most scheduled runs executed zero trades. The one fill was a buy of 29 shares of BAC at $51 on 2026-10-14. As of 2026-10-15 the book held roughly $8,516 in cash against a total value of $10,016.75 — up about 0.17%, i.e. essentially flat. That is far too short a window to read anything into.
Backtest and validation
The historical record is the real story. Over 1,279 days the strategy returned 52.62% (8.69% CAGR), with a Sharpe of 1.03, a 70.55% win rate across 294 trades, and a contained 10.38% max drawdown. Validation is genuinely strong: all four walk-forward folds were positive, the deflated Sharpe survives 42 trials (PSR 0.991), and the two most recent folds are the best — fold 3 returned 26.26% (Sharpe 1.84) and fold 4 returned 16.75% (Sharpe 1.91) with just a 2.39% drawdown.
Strengths and risks
The strengths are clear: a research-backed thesis, a high win rate, shallow drawdowns, and out-of-sample Sharpe that improves rather than decays. But balance demands caution. The edge is lopsided — folds 1 and 2 (spanning the 2022 drawdown and the recovery) returned only 4.96% and 1.91% at Sharpe ~0.35. Much of the headline return is concentrated in 2024–2026, which raises a regime-dependence question. The deflated Sharpe ratio of 0.563 is respectable but not overwhelming after 42 trials. Turnover is a hefty 4,192%, and the reviewer noted a non-zero-price guard gap and a budget-versus-equity sizing nuance worth tightening. SilentDip looks promising — but it has yet to prove itself on live capital.